<i>BRAF</i> Mutation and <i>CDKN2A</i> Deletion Define a Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma

Abstract

BRAF V600E mutations and CDKN2A deletions constitute a clinically distinct subtype of sHGG. The prolonged course to transformation for BRAF V600E PLGGs provides an opportunity for surgical interventions, surveillance, and targeted therapies to mitigate the outcome of sHGG.